Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis

Arthritis Care and Research

Volumn 66, Issue 3, 2014, Pages 344-354

  Ogata, Atsushi ^a   Tanimura, Kazuhide ^b   Sugimoto, Toyohiko ^c   Inoue, Hiroshi ^d   Urata, Yukitomo ^e   Matsubara, Tsukasa ^f   Kondo, Masakazu ^g   Ueki, Yukitaka ^h   Iwahashi, Mitsuhiro ⁱ   Tohma, Shigeto ^j   Ohta, Shuji ^k   Saeki, Yukihiko ^l   Tanaka, Toshio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO MEDICAL CENTER   (Japan)

^c SHIMOSHIZU HOSPITAL   (Japan)

^d Inoue Hospital   (Japan)

^e Seihoku Chuo Hospital   (Japan)

^f Matsubara Mayflower Hospital   (Japan)

^g Kondo Clinic of Rheumatology and Orthopaedic Surgery   (Japan)

^h SASEBO CHUO HOSPITAL   (Japan)

ⁱ Higashihiroshima Memorial Hospital   (Japan)

^j SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^k Taga General Hospital   (Japan)

^l MINAMI OSAKA GENERAL HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; DRUG ANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TOCILIZUMAB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANTIBODY DETECTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN CONTUSION; BRAIN HEMORRHAGE; CELLULITIS; CHOLESTEROL BLOOD LEVEL; CHRONIC BRONCHITIS; CLINICAL DISEASE ACTIVITY INDEX; CLINICAL EFFECTIVENESS; COLON POLYP; CONTROLLED STUDY; DAS28; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOOT MALFORMATION; GASTROENTERITIS; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HERPES ZOSTER; HUMAN; HYPERTENSION; HYPONATREMIA; IMMUNOGENICITY; INFECTION; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; INJECTION SITE URTICARIA; INTESTINE PERFORATION; ISCHEMIC COLITIS; JAPANESE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MENIERE DISEASE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NEUTROPHIL; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PLEURISY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SUBDURAL HEMATOMA; SYNOVITIS; VERTEBRAL CANAL STENOSIS; VOMITING; YOUNG ADULT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84896689880     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22110     Document Type: Article

References (32)

1. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97.
2. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study. Arthritis Rheum 2008; 58: 2968-80.
3. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-23.
4. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63: 609-21.
5. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69: 88-96.
6. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162-7.
7. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009; 19: 12-9.
8. Boonen A, van de Rest J, Dequeker J, van der Linden S,. How Renoir coped with rheumatoid arthritis. BMJ 1997; 315: 1704-8.
9. Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013; 72: 43-50.
10. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
11. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
12. Barton JL,. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence 2009; 3: 335-44.
13. Chilton F, Collett RA,. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 2008; 6: 1-14.
14. Williams EL, Edwards CJ,. Patient preferences in choosing anti-TNF therapies-R1 [letter]. Rheumatology (Oxford) 2006; 45: 1575-6.
15. Ohta S, Tsuru T, Terao K, Mogi S, Suzaki M, Nakashima H, et al. Optimal dose prediction by pharmacokinetic and biomarker response of subcutaneous tocilizumab treatment: a phase I/II study evaluating the safety, pharmacokinetics and clinical response in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2010; 62 Suppl: S467-8.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
17. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
18. Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum 2003; 49: 784-8.
19. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T,. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman's disease. Blood 2008; 112: 3959-64.
20. Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J,. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. Clin Ther 2010; 32: 1597-609.
21. International Conference on Harmonisation E9 Expert Working Group. ICH Harmonised Tripartite Guideline: statistical principles for clinical trials. Stat Med 1999; 18: 1905-42.
22. Burmester GR, Rubbert-Roth A, Cantagrel AG, Hall S, Leszczynski P, Feldman D, et al. A randomized, double-blind, parallel group study of the safety and efficacy of tocilizumab SC versus tocilizumab IV, in combination with traditional Dmards in patients with moderate to severe RA [abstract]. Arthritis Rheum 2012; 64 Suppl: S1075.
23. Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Rowell L, et al. A randomized, double-blind, parallel-group study of the safety and efficacy of tocilizumab subcutaneous versus placebo in combination with traditional DMARDs in patients with moderate to severe rheumatoid arthritis (BREVACTA). Presented at the 76th Annual Scientific Meeting of the American College of Rheumatology; 2012 November 9-14; Washington, DC.
24. Genentech, Inc.(a member of the Roche Group). Actemra prescribing information. South San Francisco: Genentech; 2010.
25. Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis 2012; 71: 817-24.
26. Miyasaka N, and the CHANGE Study Investigators. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. Mod Rheumatol 2008; 18: 252-62.
27. Takamura A, Hirata S, Nagasawa H, Kameda H, Seto Y, Atsumi T, et al. A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology. Mod Rheumatol 2013; 23: 297-303.
28. Harigai M, Takamura A, Atsumi T, Dohi M, Hirata S, Kameda H, et al. Elevation of KL-6 serum levels in clinical trials of tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a report from the Japan College of Rheumatology Ad Hoc Committee for Safety of Biological DMARDs. Mod Rheumatol 2013; 23: 284-96.
29. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6.
30. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 2010; 69: 817-21.
31. Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007; 25: 40-6.
32. Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, et al. Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase IIIb ALLOW study). Ann Rheum Dis 2012; 71: 38-44.